VENUS REMEDIES Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Quarterly Results    (VSRM)

Here are the latest quarterly results of VENUS REMEDIES. For more details, see the VENUS REMEDIES financial fact sheet and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

VENUS REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Dec-19
*
3
Mar-20
*
3
Jun-20
*
3
Sep-20
*
3
Dec-20
*
3
Mar-21
*
3
Jun-21
*
3
Sep-21
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m9698311,8871,2611,2191,1141,2982,026 
Other income Rs m18142012318352029 
Turnover Rs m9868441,9081,3831,2381,1491,3182,055 
Expenses Rs m8617551,6821,1541,0391,0691,1301,753 
Gross profit Rs m108-13114182225250168273 
Depreciation Rs m8565868687948687 
Interest Rs m41-182974181010 
Profit before tax Rs m0-4620145139182100215 
Tax Rs m10801522-169-17-17 
Profit after tax Rs m-10-5420130117351117231 
Gross profit margin %11.1-1.56.014.518.522.513.013.5 
Effective tax rate %4,104.2-17.90.010.315.9-92.9-16.7-7.9 
Net profit margin %-1.0-6.51.010.39.631.59.011.4 
Diluted EPS Rs -0.7 -4.0 1.5 9.7 8.7 26.3 8.8 17.3  
Diluted EPS (TTM) Rs -11.2 -7.5 -3.0 6.5 15.9 46.2 53.5 61.1  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster

Read: VENUS REMEDIES 4QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   SUN PHARMA    AUROBINDO PHARMA    CIPLA    DR. REDDYS LAB    PIRAMAL ENTERPRISES    

Compare VENUS REMEDIES With:   SUN PHARMA    AUROBINDO PHARMA    CIPLA    DR. REDDYS LAB    PIRAMAL ENTERPRISES    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Views on news

VENUS REMEDIES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 2, 2021 | Updated on Nov 2, 2021

Here's an analysis of the annual report of VENUS REMEDIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks (Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 21, 2022 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - DECCAN HEALTH CARE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS